Biogen BIIB Contract manufacturing, royalty and other revenue — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Biogen in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Biogen’s 10-K, filed February 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Biogen's contract manufacturing, royalty and other revenue — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Biogen's contract manufacturing, royalty and other revenue — revenue?
- Biogen (BIIB) reported contract manufacturing, royalty and other revenue — revenue of $183.23M in Q4 2025.
- How has Biogen's contract manufacturing, royalty and other revenue — revenue changed year-over-year?
- Biogen's contract manufacturing, royalty and other revenue — revenue increased by 12.3% year-over-year, from $163.15M to $183.23M.
- What is the long-term trend for Biogen's contract manufacturing, royalty and other revenue — revenue?
- Over 4 years (2021 to 2025), Biogen's contract manufacturing, royalty and other revenue — revenue has grown at a 11.4% compound annual growth rate (CAGR), from $476.3M to $732.9M.
- What does contract manufacturing, royalty and other revenue — revenue mean?
- This metric tracks the specific revenue recognized from contract manufacturing arrangements and royalty payments derived from third-party use of the company's proprietary technologies. It serves as a measure of the company's secondary revenue streams that do not stem from direct commercialization of its own primary product portfolio. Monitoring this helps investors assess the stability and growth potential of income derived from partnerships and manufacturing service agreements.